

Overview of Diabetic Retinopathy (DR)

Resource	Address
American Diabetes Association (ADA). Diabetes overview: Eye complications.	https://www.diabetes.org/diabetes/complications/eye-complications
Centers for Disease Control and Prevention (CDC). National diabetes statistics report. Last reviewed January 18, 2022.	https://www.cdc.gov/diabetes/data/statistics-report/index.html
Centers for Disease Control and Prevention (CDC). National diabetes statistics report. Prevalence of diagnosed diabetes. Last reviewed December 29, 2021.	https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-diabetes.html
Centers for Disease Control and Prevention (CDC). National diabetes statistics report. Prevalence of both diagnosed and undiagnosed diabetes. Last reviewed December 29, 21.	https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-undiagnosed-diabetes.html
Centers for Disease Control and Prevention (CDC). National Diabetes Education Program (NDEP). Working together to manage diabetes: A toolkit for pharmacy, podiatry, optometry, and dentistry. January 2014.	https://www.cdc.gov/diabetes/ndep/pdfs/working-together-to-manage-diabetes_2014.pdf
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. <i>Ophthalmology</i> . 2020;127(1):P66-P145.	https://www.aaojournal.org/article/S0161-6420(19)32092-5/fulltext
Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. <i>Diabetes Care</i> . 2018;41(11):2370-2376.	https://diabetesjournals.org/care/article/41/11/2370/36582/Association-of-Time-in-Range-as-Assessed-by
National Institutes of Health (NIH). National Eye Institute (NEI). Diabetic retinopathy. Last updated July 8, 2022.	https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy
Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: Insights from yesterday, today, and future trends. <i>Popul Health Manag</i> . 2017;20(1):6-12.	https://www.liebertpub.com/doi/10.1089/pop.2015.0181
Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: New perspectives and challenges. <i>Lancet Diabetes Endocrinol</i> . 2020;8(4):337-347.	https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30411-5/fulltext

Screening and Referral for DR

Resource	Address
Chen AJ, Hwang V, Law PY, Stewart JM, Chao DL. Factors associated with non-compliance for diabetic retinopathy follow-up in an urban safety-net hospital. <i>Ophthalmic Epidemiol</i> . 2018;25(5-6):443-450.	https://www.tandfonline.com/doi/abs/10.1080/09286586.2018.1504311?journalCode=iope20
Fox CR, Kronenberg K, Weiskopf ES. Using telemedicine to increase eye care screening & referral for people with diabetes. <i>J Pub Health Issue Pract</i> . 2019;3:137.	https://gexinonline.com/uploads/articles/Article_JP_HIP-137.pdf

Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. <i>Arch Ophthalmol</i> . 2012;130(9):1145-1152.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/1149409
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. <i>Ophthalmology</i> . 2020;127(1):P66-P145.	https://www.aaojournal.org/article/S0161-6420(19)32092-5/fulltext
International Council of Ophthalmology (ICO). ICO Guidelines for Diabetic Eye Care. Updated 2017.	https://www.idf.org/component/attachments/attachments.html?id=407&task=download

Early Treatment for DR

Resource	Address
Brown DM, Wykoff CC, Boyer D, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: Results from the PANORAMA randomized clinical trial. <i>JAMA Ophthalmol</i> . 2021;139(9):946-955.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2782556
Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. <i>Ophthalmology</i> . 2014;121(9):1783-1789.	https://www.aaojournal.org/article/S0161-6420(14)00245-0/fulltext
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. <i>Ophthalmology</i> . 2020;127(1):P66-P145.	https://www.aaojournal.org/article/S0161-6420(19)32092-5/fulltext
Gupta P, Aravindhan A, Gand ATL, et al. Association between the severity of diabetic retinopathy and falls in an Asian population with diabetes: The Singapore Epidemiology of Eye Diseases study. <i>JAMA Ophthalmol</i> . 2017;135(12):1410-1416.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2663389
Ho AC, Albin TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good. <i>JAMA Ophthalmol</i> . 2017;135(3):268-273.	https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2597594
Maturi RK, Glassman AR, Josic K, et al. Effect of intravitreal anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The Protocol W randomized clinical trial. <i>JAMA Ophthalmol</i> . 2021;139(7):701-712.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2778074
Mazhar K, Varma R, Choudhury F, et al. Severity of diabetic retinopathy and health-related quality of life: The Los Angeles Latino Eye Study. <i>Ophthalmology</i> . 2011;118:649-655.	https://www.aaojournal.org/article/S0161-6420(10)00819-5/fulltext

National Institutes of Health (NIH). National Eye Institute (NEI). What you should know. Treating diabetic retinopathy.	https://www.nei.nih.gov/sites/default/files/nehep-pdfs/DR_Tip_Sheet_FINAL_web.pdf
Patel JJ, Jenkins L, Benjamin L, Webber S. Dilated pupils and loss of accommodation following diode panretinal photocoagulation with sub-tenon local anaesthetic in four cases. <i>Eye</i> . 2002;16(5):628-632.	https://www.nature.com/articles/6700004
Reddy SV, Husain D. Panretinal photocoagulation: A review of complications. <i>Semin Ophthalmol</i> . 2018;33(1):83-88.	https://www.tandfonline.com/doi/abs/10.1080/08820538.2017.1353820?journalCode=isio20
Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. <i>World J Diabetes</i> . 2016;7(16):333-341.	https://www.wjnet.com/1948-9358/full/v7/i16/333.htm
Willis JR, Doan QV, Gleeson M, et al. Vision-related functional burden of diabetic retinopathy across severity levels in the United States. <i>JAMA Ophthalmol</i> . 2017;135(9):926-932.	https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2643965
Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. <i>Ophthalmology</i> . 2018;125(10):1608-1622.	https://www.aaojournal.org/article/S0161-6420(17)33523-6/fulltext
Wykoff CC. Management of diabetes-related retinopathy. In: <i>Prevention and management of diabetes-related eye disease</i> . American Diabetes Association; May 2019.	https://www.ncbi.nlm.nih.gov/books/NBK544520/
Yokenawa Y, Modi YS, Kim LA, Skondra D, Kim JE, Wykoff CC. American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema. <i>J Vitreoretin Dis</i> . 2020;4(2):125-135.	https://journals.sagepub.com/doi/10.1177/2474126419893829

Vascular Endothelial Growth Factor (VEGF) and DR

Resource	Address
Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. <i>N Engl J Med</i> . 1994;331(22):1480-1487.	https://www.nejm.org/doi/full/10.1056/NEJM199412013312203
Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. <i>Pharmacol Res</i> . 2016;103:253-269.	https://www.sciencedirect.com/science/article/pii/S1043661815002856

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. <i>Nature</i> . 2011;473(7347):298-307.	https://www.nature.com/articles/nature10144
Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. <i>Nat Rev Clin Oncol</i> . 2009;6(8):465-477.	https://www.nature.com/articles/nrclinonc.2009.94
Moshfeghi AA. Safety of intravitreal anti-VEGF agents. <i>Rev Ophthalmol</i> . November 11, 2014.	https://www.reviewofophthalmology.com/article/safety-of-intravitreal-antivegf-agents
Turbert D. Anti-VEGF treatments. <i>AAO EyeSmart</i> . March 2, 2019.	https://www.aao.org/eye-health/drugs/anti-vegf-treatments
WillsEye Hospital. Diabetic Retinopathy – Treatment.	https://www.willseye.org/diabetic-retinopathy-treatment/
Wirotko B, Wong TY, Simó R. Vascular endothelial growth factor and diabetic complications. <i>Prog Retin Eye Res</i> . 2008;27(6):608-621.	https://www.sciencedirect.com/science/article/abs/pii/S1350946208000542

Multidisciplinary Care in DR

Resource	Address
Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> . 2007;30(7):1742-1746.	https://diabetesjournals.org/care/article/30/7/1742/26465/Diabetic-Retinopathy-and-the-Risk-of-Coronary
Chou CF, Sherrod CE, Zhang X, et al. Barriers to eye care among people aged 40 years and older with diagnosed diabetes, 2006-2010. <i>Diabetes Care</i> . 2014;37(1):180-188.	https://diabetesjournals.org/care/article/37/1/180/31810/Barriers-to-Eye-Care-Among-People-Aged-40-Years
Diabetes In Control. Reduction in risk of diabetic complications per 1% decrease in HbA1c. April 22, 2002.	http://www.diabetesincontrol.com/reduction-in-risk-of-diabetic-complications-per-1-decrease-in/
Fenwick EK, Pesudovs K, Khadka J, et al. The impact of diabetic retinopathy on quality of life: Qualitative findings from an item bank development project. <i>Qual Life Res</i> . 2012;21(10):1771-1782.	https://link.springer.com/article/10.1007/s11136-012-0110-1
Gaedt Thorlund M, Borg Madsen M, Green A, Sjølie AK, Grauslund J. Is smoking a risk factor for proliferative diabetic retinopathy in type 1 diabetes? <i>Ophthalmologica</i> . 2013;230(1):50-54.	https://www.karger.com/Article/Abstract/350813
International Council of Ophthalmology (ICO). ICO Guidelines for Diabetic Eye Care. Updated 2017.	https://www.idf.org/component/attachments/attachments.html?id=407&task=download
Kawaskai R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: The Japan Diabetes Complications Study. <i>Ophthalmology</i> . 2013;120(3):574-582.	https://www.aaojournal.org/article/S0161-6420(12)00813-5/fulltext
Morrison JL, Hodgson LA, Lim LL, Al-Qureshi S. Diabetic retinopathy in pregnancy: A review. <i>Clin Exp Ophthalmol</i> . 2016;44(4):321-324.	https://onlinelibrary.wiley.com/doi/10.1111/ceo.12760

Storey PP, Murchison AP, Pizzi LT, et al. Impact of physician communication on diabetic eye examination adherence: Results from a retrospective cohort analysis. *Retina*. 2016;36(1):20-27.

https://journals.lww.com/retinajournal/Abstract/2016/01000/IMPACT_OF_PHYSICIAN_COMMUNICATION_ON_DIABETIC_EYE.3.aspx